Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403546 | 0.99 | KMT2A (0.68) | KMT2AEPHX2TGM2TLR2TLR1 | |
| SCHEMBL7402885 | 0.95 | KMT2A (0.66) | KMT2AEPHX2TGM2CASP3FABP7 | |
| SCHEMBL7402295 | 0.90 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL793384 | 0.90 | KMT2A (0.85) | KMT2AEPHX2TLR2TLR1CASP3 | |
| SCHEMBL12833414 | 0.89 | KMT2A (0.72) | KMT2AEPHX2TGM2TLR2TLR1 | |
| SCHEMBL4983472 | 0.88 | KMT2A (0.70) | KMT2AEPHX2TGM2TLR2TLR1 | |
| SCHEMBL31652687 | 0.88 | KMT2A (0.70) | KMT2AEPHX2TLR2TLR1CASP3 | |
| SCHEMBL27928895 | 0.88 | KMT2A (0.70) | KMT2AEPHX2TLR2TLR1CASP3 | |
| SCHEMBL17130452 | 0.86 | KMT2A (0.60) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL8762032 | 0.86 | KMT2A (0.75) | KMT2AEPHX2TGM2TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951963-B2 | Process for preparing N-protected β-amino aldehyde compounds | THERAVANCE, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| WO-2003106399-A2 | PROCESS FOR PREPARING N-PROTECTED β-AMINO ALDEHYDE COMPOUNDS | THERAVANCE, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030233010-A1 | Process for perparing N-protected beta-amino aldehyde compounds | CUMBERLAND PHARMACEUTICALS INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233010-A1 | Process for perparing N-protected beta-amino aldehyde compounds | DNPEP, PREP, ANPEP | KMT2A 2254/4885EPHX2 2302/4885TGM2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.